Placebo (matched to NNC0487-0111)

DRUG5 trials

Sponsors

Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2ObesityOsteoarthritis, KneeOverweight

Phase 1

A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity

Not yet recruitingNCT07508020

Novo Nordisk A/SObesity

Start: 2026-03-30End: 2028-01-22Target: 120Updated: 2026-04-02

Phase 3

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

RecruitingNCT07339423

Novo Nordisk A/SObesity

Start: 2026-02-24End: 2029-08-21Target: 1150Updated: 2026-03-04

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Not yet recruitingNCT07400107

Novo Nordisk A/SDiabetes Mellitus, Type 2, Obesity, Overweight

Start: 2026-05-20End: 2029-01-26Target: 1000Updated: 2026-03-12

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

Not yet recruitingNCT07503210

Novo Nordisk A/SObesity

Start: 2026-04-21End: 2028-07-04Target: 600Updated: 2026-03-31

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Not yet recruitingNCT07509307

Novo Nordisk A/SObesity, Osteoarthritis, Knee, Overweight

Start: 2026-04-13End: 2028-07-17Target: 400Updated: 2026-04-03